These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 25656607)
1. Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study. Ben Néjima D; Ben Zarkouna Y; Gammoudi A; Manai M; Boussen H Tumour Biol; 2015 May; 36(5):3815-22. PubMed ID: 25656607 [TBL] [Abstract][Full Text] [Related]
2. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Zhou Y; Yu C; Miao X; Tan W; Liang G; Xiong P; Sun T; Lin D Carcinogenesis; 2004 Mar; 25(3):399-404. PubMed ID: 14604886 [TBL] [Abstract][Full Text] [Related]
3. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. O-Charoenrat P; Khantapura P Oral Oncol; 2006 Mar; 42(3):257-67. PubMed ID: 16275157 [TBL] [Abstract][Full Text] [Related]
4. [Study on the association of SNPs of MMP-2 and TIMP-2 genes with the risk of endometriosis and adenomyosis]. Zhao XW; Li Y; Wang N; Zhao J; Li XL; Liu Q; Jia JH; Yang ZF; Kang S Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Jun; 25(3):280-3. PubMed ID: 18543216 [TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma. Diao LP; Ma H; Wei GC; Li T; Liu HS; Liu LH; Wu LL; Zhao GM; Gao YH Int J Cancer; 2012 Sep; 131(5):1095-103. PubMed ID: 22020421 [TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer. Rahimi Z; Yari K; Rahimi Z Asian Pac J Cancer Prev; 2015; 16(3):1175-9. PubMed ID: 25735351 [TBL] [Abstract][Full Text] [Related]
7. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. Srivastava P; Kapoor R; Mittal RD Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201 [TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the Promoters of the MMP-2 and TIMP-2 Genes Are Associated with Spontaneous Deep Intracerebral Hemorrhage in the Taiwan Population. Chen YC; Ho WM; Lee YS; Chen HW; Chen CM PLoS One; 2015; 10(11):e0142482. PubMed ID: 26551785 [TBL] [Abstract][Full Text] [Related]
9. The MMP-2 -735 C allele is a risk factor for susceptibility to breast cancer. Yari K; Rahimi Z; Moradi MT; Rahimi Z Asian Pac J Cancer Prev; 2014; 15(15):6199-203. PubMed ID: 25124598 [TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Przybylowska K; Kluczna A; Zadrozny M; Krawczyk T; Kulig A; Rykala J; Kolacinska A; Morawiec Z; Drzewoski J; Blasiak J Breast Cancer Res Treat; 2006 Jan; 95(1):65-72. PubMed ID: 16267613 [TBL] [Abstract][Full Text] [Related]
11. Strong association of tissue inhibitor of metalloproteinase (TIMP)-2 and -3 promoter single nucleotide polymorphisms with risk of colorectal cancer in ethnic Kashmiri population - a case control study. Banday MZ; Sameer AS Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988064 [No Abstract] [Full Text] [Related]
12. rs3918242 variant genotype frequency and increased TIMP-2 and MMP-9 expression are positively correlated with cancer invasion in urinary bladder cancer. Pençe S; Özbek E; Ozan Tiryakioğlu N; Ersoy Tunali N; Pençe HH; Tunali H Cell Mol Biol (Noisy-le-grand); 2017 Sep; 63(9):46-52. PubMed ID: 28980922 [TBL] [Abstract][Full Text] [Related]
13. Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer. Zhang M; Teng XD; Guo XX; Li ZG; Han JG; Yao L Breast; 2013 Jun; 22(3):330-4. PubMed ID: 22995648 [TBL] [Abstract][Full Text] [Related]
14. [Association of SNPs in the promoter of MMP-2 and TIMP-2 genes with epithelial ovarian cancer]. Li XL; Kang S; Zhao XW; Zhang XJ; Zhou RM; Wang N; Jia JH; Zhao J; Li Y Yi Chuan; 2008 Apr; 30(4):455-62. PubMed ID: 18424416 [TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance]. Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934 [TBL] [Abstract][Full Text] [Related]
16. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Ghilardi G; Biondi ML; Caputo M; Leviti S; DeMonti M; Guagnellini E; Scorza R Clin Cancer Res; 2002 Dec; 8(12):3820-3. PubMed ID: 12473595 [TBL] [Abstract][Full Text] [Related]
17. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration. Oszajca K; Szemraj M; Szemraj J; Jurowski P Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322 [TBL] [Abstract][Full Text] [Related]
18. The GC + CC genotype at position -418 in TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is genetic predisposing factors for prevalence of moyamoya disease. Park YS; Jeon YJ; Kim HS; Han IB; Oh SH; Kim DS; Kim NK BMC Neurol; 2014 Oct; 14():180. PubMed ID: 25280484 [TBL] [Abstract][Full Text] [Related]
19. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Gai X; Zhang Z; Liang Y; Chen Z; Yang X; Hou J; Lan X; Zheng W; Hou J; Huang M Clin Chim Acta; 2010 May; 411(9-10):719-24. PubMed ID: 20138860 [TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma]. Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]